

RILEXINE DC 375 MG INTRAMAMMARY SUSPENSION FOR DRY COWS

Authorised

- Cephalexin benzathine

Product identification

Medicine name:

RILEXINE DC 375 MG INTRAMAMMARY SUSPENSION FOR DRY COWS
Rilexine DC, 375 mg, intramaminė suspensija užtrūkusioms karvėms

Active substance:

Cephalexin benzathine

Target species:

Cattle (dry cow)

Route of administration:

Intramammary use

Product details

Active substance and strength:

Cephalexin benzathine
500.00 milligram(s) / 1.00 Syringe

Pharmaceutical form:

Intramammary suspension

Withdrawal period by route of administration:**Intramammary use:**

-

Cattle (dry cow)

- Meat and offal. 4 day Meat and offal: 4 days
 - Milk. 43 day 42.5 days after treatment when dry period is 42 days or less
 - Milk. 12 hour 12 hours after calving when dry period is more than 42 days
-

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ51DB01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Lithuania

Available in:

Lithuania

Package description:

Box of 12 x 8g intramammary syringes and 12 cleaning towels

Box of 60 x 8g intramammary syringes and 60 cleaning towels

Box of 24 x 8g intramammary syringes and 24 cleaning towels

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Virbac

Marketing authorisation date:

5/04/2022

Manufacturing sites for batch release:

Haupt Pharma Latina S.r.l.

Virbac

Responsible authority:

State Food And Veterinary Service

Authorisation number:

LT/2/22/2703/001-003

Date of authorisation status change:

5/04/2022

Reference member state:

France

Procedure number:

FR/V/0438/001

Concerned member states:

Austria Belgium Bulgaria Croatia Czechia Denmark Estonia Finland
Germany Hungary Ireland Italy Latvia Lithuania Netherlands Poland
Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

RV2703.pdf